What question did this study set out to answer?

To assess the direct effects of the vasoconstrictor peptide endothelin-1 on systemic and pulmonary hemodynamics, ventricular function, and neurohormonal activity in healthy humans.

February 1, 1997Cardiovascular ResearchOpen Access

Cardiopulmonary effects of endothelin-1 in man

View Full Paper

Ask AI

Bookmark

Why the study?

Does systemic infusion of endothelin-1 alter pulmonary and systemic hemodynamics and cardiovascular performance in healthy male volunteers?

Population

10 healthy male volunteers

Comparison

Systemic infusion of endothelin-1 vs Saline placebo

Design

RCT, randomised, cross-over, double-blind

Follow-up

30 min per dose

Authors

DKDavid G. KielyVascular Medicine

Discussion

Member takes

Implication

Endothelin-1 impairs hemodynamics and cardiac performance in humans; extends mechanistic evidence supporting endothelin antagonism in disease.

Key Points

To assess the direct effects of the vasoconstrictor peptide endothelin-1 on systemic and pulmonary hemodynamics, ventricular function, and neurohormonal activity in healthy humans.
Randomized, double-blind, placebo-controlled, crossover study in 10 healthy male volunteers.
Participants received systemic infusions of either endothelin-1 (0.75, 1.5, and 3 pmol·kg⁻¹·min⁻¹ for 30 minutes per dose) or saline placebo.
Hemodynamics, left and right ventricular diastolic filling, and myocardial inotropic indices were assessed non-invasively using pulsed-wave Doppler alongside neurohormonal assays.
Endothelin-1 induced dose-dependent declines in heart rate, stroke volume, and cardiac output, while systemic vascular resistance increased from 1156 ± 57 to 1738 ± 115 dyn·s·cm⁻⁵ and pulmonary vascular resistance rose from 142 ± 12 to 329 ± 22 dyn·s·cm⁻⁵.
Both left and right ventricular diastolic filling and electromechanical inotropic indices were significantly impaired, with diastolic filling abnormalities emerging even at low doses lacking pressor effects.
Renin-angiotensin system activity was significantly suppressed following endothelin-1 administration, whereas plasma atrial natriuretic peptide levels remained unchanged.

Structured PICO

Does systemic infusion of endothelin-1 alter pulmonary and systemic hemodynamics and cardiovascular performance in healthy male volunteers?

Population

10 healthy male volunteers

Intervention

Systemic infusion of endothelin-1 (0.75, 1.5 and 3 pmol.kg-1.min-1 for 30 min each)

Comparator

Saline placebo

Outcome

Systemic and pulmonary haemodynamic parameters, left and right ventricular diastolic filling, and inotropic statesurrogate

Endothelin-1 infusion in healthy men causes systemic and pulmonary vasoconstriction, impairs diastolic filling, and acts as a negative inotrope.

Cite This Study

David G. Kiely (1997) studied this question.

synapsesocial.com/papers/6a89ced7b11dee029fbd5d2a https://doi.org/10.1016/s0008-6363(96)00219-2

View Full Paper

Ask AI

Bookmark

Implication

Endothelin-1 impairs hemodynamics and cardiac performance in humans; extends mechanistic evidence supporting endothelin antagonism in disease.

Cardiopulmonary effects of endothelin-1 in man

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Cardiopulmonary effects of endothelin-1 in man

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider